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Mice deficient in adipose triglyceride lipase (ATGL−/−) present elevated ectopic lipid levels but are paradoxically glucose-tolerant.
Measurement of endogenous glucose production (EGP) and Cori cycle activity provide insights into the maintenance of glycemic
control in these animals. These parameters were determined in 7 wild-type (ATGL+/−) and 6 ATGL−/− mice by a primed-infusion
of [U-13C
6
]glucose followed by LC-MS/MS targeted mass-isotopomer analysis of blood glucose. EGP was quantified by isotope
dilution of [U-13C
6
]glucose while Cori cycling was estimated by analysis of glucose triose 13C-isotopomers. Fasting plasma free
fatty-acids were significantly lower in ATGL−/− versus control mice (0.43 ± 0.05mM versus 0.73 ± 0.11mM, 𝑃 < 0.05). Six-hour
fasting EGP rates were identical for both ATGL−/− and control mice (79 ± 11 versus 71 ± 7 𝜇mol/kg/min, resp.). Peripheral glucose
metabolismwas dominated byCori cycling (80± 2%and 82± 7%of glucose disposal forATGL−/− and controlmice, resp.) indicating
that peripheral glucose oxidation was not significantly upregulated in ATGL−/− mice under these conditions. The glucose 13C-
isotopomer distributions in bothATGL−/− and controlmicewere consistent with extensive hepatic pyruvate recycling.This suggests
that gluconeogenic outflow from the Krebs cycle was also well compensated in ATGL−/− mice.
1. Introduction
The ectopic accumulation of lipids in tissues such as the
skeletal muscle and liver is highly implicated in the pathogen-
esis of insulin resistance and glucose intolerance. In skeletal
muscle, elevated levels of intramyocellular lipids are strongly
associated with impaired rates of insulin-stimulated whole-
body glucose disposal [1]. In the liver, excessive intracellular
lipid levels are associated with impaired insulin-mediated
suppression of glucose production [2]. However, there are
settings where elevated tissue lipid levels do not confer
insulin resistance, most notably the “athlete’s paradox” where
highly trained athletes have elevated levels of intramyocel-
lular triglyceride yet are highly insulin sensitive [3, 4].
A similar paradox is presented in subjects with loss of func-
tionmutations in the adipose triglyceride lipase (ATGL) gene
[5]. ATGL is the rate-limiting enzyme for triglyceride catabo-
lism in most cells and tissues and a lack of ATGL activity
results in a dyslipidemic phenotype with augmented visceral
adipose tissue and extensive ectopic triglyceride accumula-
tion in pancreas and skeletal muscle [5]. These subjects,
though glucose intolerant on account of a limited insulin
secretory response, nevertheless show normal whole-body
insulin sensitivity [5]. This profile is recapitulated in the
ATGL knockout (ATGL−/−) mouse model. These mice show
augmented adipose tissue mass, as well as extensive ectopic
triglyceride accumulation in heart, liver, and skeletal muscle
[6, 7]. The excessive myocardial triglyceride accumulation is
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Figure 1: Schematic of plasma glucose 13C-isotopomer formation following infusion of [U-13C
6
]glucose (represented by black closed circles),
its initial conversion to [1,2,3-13C
3
]pyruvate and lactate via glycolysis, and gluconeogenic conversion of this isotopomer to form M+2 and
M+3 glucose isotopomers (shown in grey).
associatedwith the development of severe cardiac insufficien-
cy at about 12 weeks of life [6]. Despite this excessive adipos-
ity, ATGL−/− mice are glucose tolerant and insulin sensitive
and the basis of this paradox remains poorly understood.
In the basal fasting state, glucose homeostasis is depen-
dent on a tight control of endogenous glucose production
(EGP) and efficient peripheral glucose disposal. The cur-
tailment of triglyceride hydrolysis in ATGL−/− mice can
potentiallymodify both liver andmuscle glucosemetabolism,
ultimately contributing to improved glucose tolerance. In
skeletal muscle, a reduction in free-fatty acid (FFA) levels
due to attenuation of triglyceride hydrolysis can potentially
favor glucose oxidation in accord with the postulations of
the Randle cycle [8], thereby promoting peripheral glucose
disposal. Meanwhile, a restriction in availability of systemic
FFA and glycerol results in restricted gluconeogenesis from
glycerol as well as pyruvate, the latter being highly dependent
on 𝛽-oxidation for ATP and reducing equivalents. It is not
known to what extent glucose tolerance in the ATGL−/−
mouse is explained by improved peripheral glucose oxidation
versus restriction of gluconeogenesis. Therefore, the aim
of this study was to compare EGP and peripheral glucose
disposal in ATGL−/− versus wild-type (WT) mice. This
was achieved by 13C-isotopomer analysis of plasma glucose
following a primed-infusion of [U-13C
6
]glucose: a tracer
that provides a measurement of EGP by isotope dilution,
as well as a measure of glucose carbon recycling via the
Cori cycle, a measure of the sparing of glucose oxidation by
peripheral tissues as illustrated by Figure 1. Plasma glucose
13C-isotopomers from blood spots were quantified by a
novel and sensitive isotopomer-targeted LC-MS/MS analysis.
Unlike GC-MS methods that require sample derivatization
[9], this analysis was achieved following a simple and rapid
sample extraction procedure.
2. Materials and Methods
All experimental procedures were approved beforehand by
the local Animal Ethics Committee of the Radboud Uni-
versity Nijmegen Medical Center (RUNMC) (Nijmegen,
Netherlands). The mice used in this project were a kind gift
of Professor Rudolf Zechner from Graz University (Graz,
Austria). ATGL−/− mice were bred from heterozygous ATGL
(ATGL+/−) in a mixed genetic background C57BL/6J and
129Ola as described previously [6]. Mice were fed ad libitum
a standard chow diet and were housed in 12 h/12 h light-dark
cycle with controlled temperature (22–24∘C). Six whole-body
knockout ATGL−/− mice and seven ATGL+/− littermates
(referred to hereafter as wild-type (WT) mice) were used
for this study. Animals were fasted for 6 h and anesthetized
with 1.5% isoflurane given by a gas mixture (2 : 1 O
2
/N
2
O)
through a facial mask.They were administered intravenously
a primed-constant infusion of [U-13C
6
]glucose consisting
of a 6.25 𝜇mol/kg priming dose followed by 5 𝜇mol/kg/min
constant infusion for 120min.
Blood spots were collected directly onto Whatman num-
ber 6 filter paper at 105, 110, and 115min. For a subgroup
of animals, blood spots were collected before the start of
tracer infusion in order to obtain background 13C levels. Six
mm blood spot disks were punched; then 50𝜇L of inter-
nal standard (IS) solution consisting of 30 𝜇M [U-13C
6
,U-
2H
7
]glucose in distilled water and 450𝜇L of EtOH were
added. Samples were sonicated in a bath for 45min at room
temperature and then centrifuged for 5min at 13,900×g.
The supernatant was evaporated at 60∘C and resuspended
in 50𝜇L of H
2
O. Samples were sonicated with a cup-horn
at 40%, for 2min, with pulses of 1 sec and pauses of 1 sec.
Samples were subsequently purified by solid phase extraction
(SPE) using reversed phase packed zip-tips and ACN/H
2
O as
the mobile phase.
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2.1. LC-MS/MS Analysis. The LC system used for all analyses
was anUltimate 3000 LC system (Thermo Scientific, Dionex).
The MS used was a hybrid triple quadrupole/linear ion trap
4000 QTRAP LC-MS/MS system equipped with an electro-
spray ionization (ESI) Turbo V ion spray source (ABSciex).
The software operating the LC system was the Chromeleon
6.80 (Thermo Scientific, Dionex) and the MS system was
controlled by the Analyst 1.5.1 (ABSciex).
Chromatographic separation was performed on a Luna
NH
2
3 𝜇m, 100 A˚, 150 × 2.00mm column. The flow rate was
150 𝜇L/min and running time for each sample was 15min.
Samples were eluted with an ACN/H
2
O gradient starting
at 80%/20%, reaching 60%/40% at 5min and 20%/80% by
15min. The retention time for glucose was approximately
8min. After sample injection, one blank (H
2
O) of 4min
running and afterwards a second blank (H
2
O) of 8min
running were injected. The sample injection was 1 𝜇L, while
for the blanks 19𝜇L was injected.
Samples were analyzed at 150 𝜇L/min by ESI. The ion-
ization source operated in the negative mode at an ion
spray voltage of 4500V, with nebulizer gas 1 pressure set
to 35 psi, nebulizer gas 2 set to 30 psi, and a temperature
of 450∘C. The 4min blank was operated in the positive
mode, while the 8min blank program was operated in the
negative mode. Glucose enrichments were quantified using
the multiple reaction monitoring (MRM) triple quadrupole
scan mode. The following MS parameters were maintained
for all transitions: collision gas 6 psi, curtain gas 30 psi,
collision cell exit potential −8 eV, entrance potential −4 eV,
dwell time 100ms, and declustering potential −50 eV. The
collision energy was optimized for each transition. MRM
transitions for monitoring [U-12C
6
]glucose were 179/89, for
[1,2-13C
2
]glucose 181/89 and 181/91, for [1,2,3-13C
3
]glucose
182/89 and 182/92, and for [U-13C
6
]glucose 185/92. Finally, for
the [U-13C
6
, U-2H
7
]glucose internal standard, the selected
transition was 192/94. Peak areas were integrated using the
Multiquant 2.1.1 software (ABSciex).
Excess enrichments of glucose 13C-isotopomers were
quantified from calibration curves prepared with known
ratios of unenriched glucose to [1,2-13C
2
]glucose, [1,2,3-
13C
3
]glucose, and [U-13C
6
]glucose. The amount of glu-
cose 13C-isotopomers measured from the calibration solu-
tions spanned the range of measured concentrations from
the blood samples. Analysis of single and combined 13C-
isotopomer standards indicated no significant cross-contam-
ination of M+6, M+3, and M+2 13C-mass isotopomer
between the different 13C-enriched glucose standards.
2.2. Quantifying Endogenous Glucose Production and Cori
Cycle Fluxes. Enrichment of plasma glucose from infused
[U-13C
6
]glucose (𝐸
𝑝
) was determined from the M+6 abun-
dance of plasma glucose. The rate of appearance (𝑅
𝑎
) of
plasma glucose and EGP were calculated as follows:
Glucose 𝑅
𝑎
=
𝐸
𝑖
𝐸
𝑝
× 𝑖,
EGP = 𝑅
𝑎
− 𝑖,
(1)
where 𝑖 is infusion rate of [U-13C
6
]glucose in 𝜇mol/kg/min
and𝐸
𝑖
is the percent enrichment of infusate [U-13C
6
]glucose.
The units of 𝑅
𝑎
and EGP were reported as 𝜇mol glucose/kg
bodyweight/min.The rate of peripheral glucose disposal (𝑅
𝑑
)
was assumed to be equal to 𝑅
𝑎
. For quantifying Cori cycle
activity, the following equations were used:
Fraction of glucose 𝑅
𝑎
undergoing Cori Cycling
= 1.5× [0.5× (M+2 +M+3)
M+6
] ,
Absolute Cori cycling flux
= Fractional Cori cycle flux×𝑅
𝑑
,
(2)
where the fraction of glucose 𝑅
𝑑
undergoing Cori cycling
is given as a percentage and the absolute Cori cycle flux is
reported as 𝜇mol/kg/min.
Plasma glucose M+6 enrichment was considered as
the precursor pool while the sum of plasma glucose M+2
and M+3 isotopomer enrichments was assumed to be the
products following passage of the M+6 species through the
Cori cycle. The M+3 species detected by the 182/92 LC-
MS/MS transitionwas assumed to represent the sumof [1,2,3-
13C
3
]glucose and [4,5,6-13C
3
]glucose isotopomers while the
M+2 species detected by the 181/91 transition was assumed to
represent the sum of [1,2-13C
2
]glucose and [5,6-13C
2
]glucose
isotopomers (Figure 1). These four species represent ∼85–
90% of glucose isotopomers that are formed during recycling
of [U-13C
6
]glucose [10, 11]. Gluconeogenesis also results in an
approximately∼1.5-fold dilution of 13C-enrichment via Krebs
cycle carbon exchange; hence a correction factor of 1.5 was
incorporated into the equation [10, 11]. Finally, since oneM+6
glucose generates two recycled molecules containing one or
the other of the M+3 and M+2 daughter isotopomers, for
calculating the recycling fluxes, the sum of M+3 and M+2
isotopomer enrichments was divided by 2 to maintain the
correct stoichiometry between the plasma glucose precursor
and recycled glucose product.
3. Results
The physiological characteristics of ATGL−/− and WT mice
are shown in Table 1. Both groups of mice were statistically
not different in age, but the ATGL−/− group tended to be
younger. This was due to some spontaneous deaths due to
heart failure occurring in this group at about 8 weeks of age in
addition to somemortalities during the tracer administration
protocol, also likely related to heart failure. Food intake was
similar for both groups. After 6 h of fasting, both groups
had equivalent fasting plasma glucose andplasma triglyceride
levels but ATGL−/− mice had significantly lower levels of
plasma FFA at 6 h of fasting compared to WT mice. The
glucose M+6, M+3, and M+2 isotopomer distributions are
summarized in Figure 2. For a subset of animals (4 ATGL−/−
and 2WT), a blood sample was collected immediately before
[U-13C
6
]glucose infusion to determine background levels of
M+2, M+3, and M+6. Based on our detection limit criteria
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Table 1: Physiological characteristics for WT and ATGL−/− mice.
Data are expressed as mean ± SEM. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
Physiological parameters WT ATGL−/−
Age (weeks) 9.9 ± 0.4 7.8 ± 2.2
Body weight (g) 26.3 ± 1.1 23.4 ± 1.2
Liver index (liver wt/body wt) 0.0335 ± 0.0019 0.0267 ± 0.0019∗
Food intake (g/g of body wt/24 h) 0.123 ± 0.019 0.128 ± 0.010
Fasting glycemia 7.8 ± 0.5 7.8 ± 0.4
Plasma triglyceride (mg/dL) 103 ± 9 90 ± 4
Plasma free-fatty acids (mM) 0.734 ± 0.11 0.425 ± 0.051∗∗
∗∗∗
∗∗
WT ATGL−/−
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Figure 2: Percent enrichment of [U-13C
6
]glucose (M+6), [1,2-
13C
2
] + [5,6-13C
2
]glucose (M+2), and [1,2,3-13C
3
] + [4,5,6-
13C
3
]glucose (M+3) inWT (𝑛 = 7) and ATGL−/− mice (𝑛 = 6). Data
are expressed as mean ± SEM. ∗𝑃 < 0.05.
(signal-to-noise ratio ≥3), no signals from any of these
isotopomers were observed in any of the samples. For blood
that was collected after [U-13C
6
]glucose infusion, most of the
variance in 13C-isotopomer enrichments reported for each
group arose fromdifferences between animals, withATGL−/−
mice showing somewhat higher variance than WT mice.
Thus, the variability in glucosemass isotopomer enrichments
between the 105-, 110-, and 115-minute blood samples for
each animal was low, with the mean coefficient of variation
being 7% for the parent M+6 isotopomer and 8% and 11%
for the daughter M+2 and M+3 isotopomers, respectively.
For both ATGL−/− and WT mice, the distribution of the
recycled glucose 13C-isotopomers was heavily skewed toward
M+2 over M+3 species (Figure 2). An excess of M+2 over
M+3 isotopomer distribution within the triose moiety of
glucose was also previously reported in rats infused with
[U-13C]lactate [12]. Also, an excess of [1,2-13C
2
]glucose over
[1,2,3-13C
3
]glucose isotopomers has been quantified by 13C
NMR in mice administered with [U-13C]propionate [13,
14], an alternative gluconeogenic substrate that, like [U-
13C]lactate, is also metabolized to glucose via the hepatic
Krebs cycle and anaplerosis.
Table 2: Glucose appearance and Cori cycling fluxes in WT and
ATGL−/− mice based on plasma glucose 13C-isotopomer analysis.
Data are expressed as mean ± SEM.
Glucose fluxes WT ATGL−/−
Glucose 𝑅
𝑎
(𝜇mol/kg/min) 70.8 ± 6.7 78.7 ± 10.6
Glucose 𝑅
𝑑
(𝜇mol/kg/min) 70.8 ± 6.7 78.7 ± 10.6
EGP (𝜇mol/kg/min) 66.4 ± 6.6 73.1 ± 10.3
Absolute Cori cycle flux (𝜇mol/kg/min) 56.6 ± 5.5 66.9 ± 12.5
Fractional Cori cycle flux (% of 𝑅
𝑑
) 79.9 ± 2.8 82.0 ± 6.6
Flux estimates derived from the 13C glucose isotopomer
distributions are shown in Table 2. No differences in either
glucose 𝑅
𝑎
or EGP rates were found between WT and
ATGL−/− mice. Our estimated EGP values are higher com-
pared to values of ∼50𝜇mol/kg/min that were previously
reported for fasted WT mice that were chronically catheter-
ized and fasted for 26 h [15]. It is known that EGP declines
during the progression of fasting [16]; hence a 6 h fasted
mousewould be expected to have higher EGP rates compared
to a 26 h fasted mouse. WT and ATGL−/− mice also had
similar rates of fractional and absolute Cori cycle fluxes.
Cori cycling accounted for the majority (∼80%) of glucose
utilization indicating that peripheral glucose oxidation was
highly spared in both groups of mice.
4. Discussion
There is a strong association between elevated ectopic lipid
levels and insulin resistance in both humans and rodents [17–
19]. Metabolites related to triglyceride-fatty acid interconver-
sion such as fatty-acyl CoA, diacylglycerol, and ceramides
have been shown to disrupt insulin signaling [20–23] and
have therefore been hypothesized as the causative agents
of insulin resistance in the setting of elevated ectopic lipid.
However, this view is challenged by the ATGL−/− mouse
since it has extensive levels of ectopic lipids in insulin-
sensitive tissues such as skeletal muscle, heart, and liver but is
nevertheless glucose tolerant. In contrast, when ectopic lipid
depots are induced in WT mice via high-fat and/or high-
sugar feeding, they develop insulin resistance and glucose
intolerance [24, 25]. In the basal fasted state, insulin sensi-
tivity is primarily defined by the matching of hepatic glucose
production to peripheral glucose uptake. With diet-induced
dyslipidemia and ectopic lipid accumulation, there is a well
characterized upregulation of fasting EGP [26, 27], primarily
due to the impaired control of hepatic gluconeogenesis. This
so-called hepatic insulin resistance is a prominent and early
feature of diet-induced glucose intolerance and is strongly
associated with elevated hepatic lipid levels. Meanwhile,
the accumulation of lipid in skeletal muscle, albeit slower
than the development of hepatic steatosis, is nevertheless
accompanied by a reduction in insulin-stimulated glucose
disposal [28].
The features of fasting glucose production and peripheral
disposal that explain the high glucose tolerance in ATGL−/−
mouse remain unclear. In the initial study on the effect of
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ATGLknockout onmetabolic status and insulin sensitivity by
Haemmerle et al. [6], ATGL−/− and WT controls had similar
levels of fasting plasma glucose and insulin. This suggests
that ATGL−/− and WT mice had similar insulin sensitivity
under fasting conditions, at least as assessed by fasting insulin
and glucose levels. However under fed conditions and also
following a glucose load, ATGL−/− mice revealed higher
insulin sensitivity compared to WT mice [6]. Since insulin-
stimulated disposal of glucose into peripheral tissues assumes
a much greater role in glycemic control under fed compared
to fasted states, this suggests that the higher insulin sensitivity
of ATGL−/− mice is more related with peripheral rather than
hepatic insulin actions. In support of this, Kienesberger et
al. reported that in vivo ATGL−/− skeletal muscle insulin
signaling was improved with increased insulin receptor sub-
strate 1 andAkt phosphorylation, PI3K andAkt activities, and
GLUT4 protein expression [29]. Interestingly, hepatic insulin
signaling was unchanged or impaired in ATGL−/− mice [29],
suggesting a more prominent role of peripheral over hepatic
insulin actions in explaining their high insulin sensitivity.
The role of extrahepatic tissues in determining whole-body
insulin sensitivity of ATGL−/− mice becomes even more
prominent under increased energetic demand since they are
more dependent on glucose as an oxidative fuel. Thus at
rest, ATGL−/− skeletal muscle ATP and other high-energy
phosphate levels were comparable to the littermates and even
upon high intense electrostimulation, the muscle oxidative
capacity was not compromised [7]. However, ATGL−/− mice
showed significantly lowermuscle glycogen levels both at rest
and after electrostimulation, further supporting an increased
demand for carbohydrate oxidation [7]. Similarly, Schoiswohl
et al. showed that exercised ATGL−/− mice presented hepatic
glycogen reserves which were severely depleted [30]. This
is consistent with an increased mobilization of glucose for
skeletal muscle oxidation in response to insufficient fatty acid
availability [30].
Conversely, the muscle-specific ATGL knockout, which
recapitulates the high intramyocellular triglyceride level of
the global ATGL−/−, did not have differences in oxida-
tive substrate selection, glucose homeostasis, or peripheral
insulin sensitivity compared to controlmice [31] while resting
muscle oxidative phosphorylation and oxidative capacity
was not compromised in global ATGL−/− mice [7]. Nev-
ertheless, when exercised, ATGL−/− mice showed limited
generation of FFA while at the same time hepatic glycogen
reserves were severely depleted [30]. This is consistent with
an increased mobilization of glucose for skeletal muscle
oxidation in response to insufficient fatty acid availability
[30]. Furthermore, ATGL−/−mice showed significantly lower
muscle glycogen levels both at rest and after electrostim-
ulation, further supporting an increased demand on car-
bohydrate reserves for muscle energy utilization [7]. Mice
that underwent liver-selective ATGL knockdown developed
steatosis following both normal and high-fat feeding but were
protected against glucose intolerance and hyperinsulinemia
during high-fat feeding [32]. While hepatic insulin signaling
in response was not modified by hepatic ATGL knockdown,
expression of gluconeogenic enzymes was decreased in both
normal and high-fat feeding settings [32] suggesting reduced
capacity for gluconeogenesis. Moreover, hepatic fatty acid
oxidation was found to be impaired in ATGL−/− mice [33],
which, by restricting the availability of ATP and reduc-
ing equivalents, would also constrain gluconeogenesis from
pyruvate precursors.
How do our measurements of fasting glucose kinetics
reconcile with these previous studies? At 6 h of fasting,
we found a significantly reduced level of plasma FFA in
ATGL−/− mice compared to WT, suggesting impairment of
fasting whole-body lipolysis. The concentration of plasma
FFA has been shown to exert strong and acute control of
gluconeogenic flux [34–36], but the reduced availability of
FFA in ATGL−/− mice did not appear to compromise EGP
fluxes, at least at 6 hours of fasting. We found that peripheral
glucose metabolism was largely directed towards the Cori
cycle, with the majority of glucose carbons being recycled.
This suggests that skeletal muscle glucose oxidation, at least
at rest, was not significantly enhanced in ATGL−/− mice but
was instead highly spared to the same extent as in wild-
types. Presumably, the production of FFA by other lipases,
for example, spillover, or the catabolism of other substrates as
amino acids was sufficient to maintain the energy demands
of skeletal muscle, at least in the resting state. A possible
confounding factor in our study is the fact that the body
weights of the ATGL−/− mice were not significantly higher
than the WT (due primarily to increased adiposity), as has
been consistently reported in previous studies, for example,
[6, 7]. This may be related to the tendency for the ATGL−/−
mice to be younger than their WT littermates as previously
described. Intramyocellular lipid (IMCL) levels were assayed
in vivo using 1H magnetic resonance spectroscopy in the
tibialis anterior muscle of 3 ATGL−/− and 4 ATGL+/− mice
of this study. ATGL−/− mice had levels of IMCL relative to
total creatine of 3.6 ± 0.44 versus 0.71 ± 0.80 in ATGL+/−
mice. Although the number of mice used for this analysis
was limited, the data supports the characteristic ectopic lipid
accumulation in ATGL−/− mice.
Whether Cori cycle and EGP fluxes are similarly sus-
tained in ATGL−/− mice during longer fasting periods or
during high-energy demanding states, for example, exercise,
remains to be investigated. Presumably, the production of
FFA by lipases other than ATGL was sufficient to maintain
the energy demands of skeletal muscle, at least in the resting
state.
In addition to providing estimates of EGP from iso-
tope dilution of [U-13C
6
]glucose, LC-MS/MS also provided
precise quantification of M+3 and M+2 triose isotopomers
associated with Cori cycling. Their abundances were quan-
tified from specific calibration curves prepared with [1,2-
13C
2
]glucose and [1,2,3-13C
3
]glucose. The fragmentation
mechanism that yields the 181/91 and 182/92 MS/MS tran-
sitions cleaves the glucose molecule into two fragments of
identical mass representing carbons [1, 2, 3] and [4, 5, 6].
Thus, the abundance of M+2 and M+3 isotopomers from
both triose halves of the glucose molecule was reported. For
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Figure 3: Generation of [2,3-13C
2
]triose-P (M+2) and [1,2,3-13C
3
]triose-P (M+3) isotopomers from [1,2,3-13C
3
]lactate via gluconeogenesis.
The intermediate isotopomers of oxaloacetate are also shown. In the absence of pyruvate cycling and with extensive exchange of oxaloacetate
with malate and fumarate, equal amounts of oxaloacetate isotopomers (a) and (b) are formed that result in the generation of equal amounts
of M+2 andM+3 triose-P isotopomers. With pyruvate cycling, equal proportions of isotopomers (a) and (b) are converted to isotopomer (c).
Since isotopomer (b) is the sole precursor of M+3 triose-P while isotopomers (a) and (c) both contribute to M+2 triose-P, this results in an
excess of M+2 over M+3 triose-P.
both WT and ATGL−/− mice, we observed a significantly
higher abundance of the glucose M+2 over the M+3 iso-
topomer. As illustrated by Figure 3, this can be explained
by an excess production of [2,3-13C
2
]triose-P over [1,2,3-
13C
3
]triose-P resulting from pyruvate cycling and is con-
cordant with high activities of pyruvate cycling that have
been described in fasted mice [13, 14], rats [37], and humans
[38–40]. 13C-isotopomer studies of glucose enriched from
[U-13C]propionate have shown that the formation of other
possible M+2 triose isotopomers (i.e., [1,2-13C
2
]triose-P and
[1,3-13C
2
]triose-P) is low relative to that of [2,3-13C
2
]triose-
P, [13, 14]. Therefore, the observed excess of M+2 over M+3
primarily involves the “first pass” isotopomers described in
Figures 1 and 3.
Previous estimates of M+2 and M+3 enrichments from
[U-13C
6
]glucose recycling in rats and humans have revealed
variable levels of M+2 and M+3 isotopomer products fol-
lowing [U-13C
6
]glucose infusion. In 24 h fasted rats infused
intraduodenally with substrate levels of [U-13C
6
]glucose, a
∼40% excess of M+2 to M+3 was found for both glucose
and glycogen [41]. However, in another study where rats
were infused intragastrically with [U-13C
6
]glucose, a small
excess ofM+3 overM+2 glucose was reported in both plasma
glucose and hepatic glycogen. A study of healthy humans
fasted for periods ranging from 12 to 40 h showed an excess
of M+3 to M+2 in 12 and 20 h fasted individuals but a 2-
fold excess of M+2 over M+3 in 40 h fasted subjects [42].
In a study of three 65 h fasted subjects, there was a modest
excess of M+2 over M+3 for two of the subjects, while the
third subject had a modest excess of M+3 over M+2 [43].
However, these human measurements were acknowledged
to have limited precision and specificity due to low 13C-
enrichment levels [42] while specific glucose M+2 and M+3
isotopomers were not independently calibrated in any of
these aforementioned human or animal studies. As with
previousGC-MS andNMR-based analyses of [U-13C]glucose
enrichment and Cori cycling, our approach is ultimately
limited by the precision of the isotopomer quantifications, in
particular the recycled M+2 and M+3 species whose levels
are typically lower than the parent [U-13C]glucose while at
the same time background contributions, in particular to
the M+2 species, are higher. Also, this approach does not
provide information on other gluconeogenic precursors such
as fructose and glycerol, which, in addition to glycogenolysis,
could influence the fractional contribution of Cori cycling to
EGP.
In summary, we quantified glucose appearance and recy-
cling fluxes in 6 h fasted ATGL−/− mice. EGP rates were sim-
ilar to WT controls indicating that hepatic gluconeogenesis
was well controlled. As for WT controls, the majority of
glucose that underwent peripheral metabolism was spared
fromoxidation.This indicates that, under these resting condi-
tions, there was sufficient availability of other substrates, pre-
sumably including fatty acids, for muscle energy generation.
Finally, resolution of recycled glucose isotopomers byMS/MS
revealed a distribution consistentwith active hepatic pyruvate
cycling for both ATGL−/− and WT mice.
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